were understandably cautious on extrapolating the results to children (the larger opportunity). Of note, no therapies arc approved for active RSV; Synagis is approved as a prophylaxis in a narrow segment of infants and very few assets are in clinical development. GS-5806 is not included in JPM or Stre

n infants or adults with RSV infection. Indeed, in children, RSV treatment guidelines issued by the American Academy of Pediatrics only recommends Synagis specifically for prophylaxis in an increasingly narrow segment of infants. Additionally, the guidelines caution that supportive therapy (inhaled br